Study ID: Amgen FOURIER 20110118

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy in Patients with Clinically Evident Cardiovascular Disease


The purpose of this study is to find out more about an investigational product called AMG 145. AMG 145 is a fully human antibody that binds to a natural protein called PCSK9 that is produced by the liver. By binding to PCSK9, AMG 145 allows the LDL receptor (a protein present in the liver) to move the LDL-cholesterol more efficiently out of the bloodstream. This study is designed to see whether treatment of dyslipidemia with AMG 145 in people who have experienced a prior myocardial infarction or stroke, and who are taking a highly effective dose of a statin, reduces the risk of recurring or additional cardiovascular events. Participants in this study have clinically evident cardiovascular disease.

Fargo Region
Principal Investigator:
David Clardy, MD
Phase III


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list